ORIGINAL RESEARCH article

Front. Immunol., 23 December 2022

Sec. Viral Immunology

Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1015271

Computer-aided drug design combined network pharmacology to explore anti-SARS-CoV-2 or anti-inflammatory targets and mechanisms of Qingfei Paidu Decoction for COVID-19

  • School of Life Science, Ludong University, Yantai, Shandong, China

Abstract

Introduction:

Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by SARS-CoV-2. Severe cases of COVID-19 are characterized by an intense inflammatory process that may ultimately lead to organ failure and patient death. Qingfei Paidu Decoction (QFPD), a traditional Chines e medicine (TCM) formula, is widely used in China as anti-SARS-CoV-2 and anti-inflammatory. However, the potential targets and mechanisms for QFPD to exert anti-SARS-CoV-2 or anti-inflammatory effects remain unclear.

Methods:

In this study, Computer-Aided Drug Design was performed to identify the antiviral or anti-inflammatory components in QFPD and their targets using Discovery Studio 2020 software. We then investigated the mechanisms associated with QFPD for treating COVID-19 with the help of multiple network pharmacology approaches.

Results and discussion:

By overlapping the targets of QFPD and COVID-19, we discovered 8 common targets (RBP4, IL1RN, TTR, FYN, SFTPD, TP53, SRPK1, and AKT1) of 62 active components in QFPD. These may represent potential targets for QFPD to exert anti-SARS-CoV-2 or anti-inflammatory effects. The result showed that QFPD might have therapeutic effects on COVID-19 by regulating viral infection, immune and inflammation-related pathways. Our work will promote the development of new drugs for COVID-19.

1 Introduction

The pandemic of Coronavirus Disease-2019 (COVID-19) has posed an unprecedented crisis to global public health (13). The main symptoms of COVID-19 infection are fever, coughing, shortness of breathing and also death (4). Traditional Chinese medicine (TCM) formulas was widely used in China against COVID-19, especially in 2020, in the absence of specific drugs and vaccines (57). Based on the current clinical investigation, the treatment of inflammatory storms has been proposed as a critical part of rescuing severe COVID-19 (811). Qingfei Paidu Decoction (QFPD) has become one of the most used compounds due to its potential role in the treatment of COVID-19 (1214). QFPD is composed of 20 herbs (15), namely Agaric (Zhuling), Oriental waterplantain tuber (Zexie), Largehead atractylodes rhizome (Baizhu), Cassia twig (Guizhi), Chinese ephedra herb (Mahuang), Semen armeniacae amarum (Xingren), Poria cocos (Fuling), Chinese thorowax root (Chaihu), Baikal skullcap root (Huangqin), Pinellinae rhizoma praeparatum (Jiangbanxia), Common ginger rhizome (Shengjiang), Tatarian aster root and rhizomes (Ziwan), Common coltsfoot flower (Kuandonghua), Blackberrglily rhizome (Shegan), Manchurian wildginger herb (Xixin), Common yam rhizome (Shanyao), Immature bitter orange (Zhishi), Wrinkled gianthyssop herb (Huoxiang), Dried tangerine peel (Chenpi), and Baked radix glycyrrhizae (Zhigancao). The combination of these herbs is used to reduce mortality and improve cure rates in patients with COVID-19 (16).

Computer-Aided Drug Design (CADD) is a method for developing lead compounds by theoretical calculation, simulation, and prediction of the relationship between drugs and receptors (17). Network pharmacology is a powerful tool to reflect the pharmacological effects and mechanisms of TCM (1820). The concept of holism for TCM has much in common with the major points of network pharmacology, in which the general “one target, one drug” mode is shifted to a new “multi-target, multi-component” mode (21). The research method of CADD combined with network pharmacology can be used to reveal the mystery of the “multi-target, multi-component and multi-path” of TCM formulas. This method greatly improves the success rate of drug research and saves the cost of drug development.

QFPD has the potential therapeutic effects for COVID-19 intervention in China, but how to take advantage of its anti-SARS-CoV-2 and anti-inflammatory effects deserves further exploration. Therefore, we aim to screen the antiviral or anti-inflammatory components in QFPD and their targets using Discovery Studio 2020 (DS2020) software. We compared the targets regulated by the active components in QFPD with the COVID-19 targets recorded in the Genecards database (https://www.genecards.org) and obtained their common targets. With the help of network pharmacology, we investigated how QFPD regulates the body from various aspects through multiple targets and multiple pathways. The results provided some vital information for the precise clinical medication and improved the therapeutic ability of TCM for COVID-19.

2 Experimental section

2.1 Screening the active components in QFPD from the database

Most active components of 20 herbs in QFPD were collected through the Traditional Chinese Medicines Database (TCMdb). It was a new tool with 23033 active components to support the modernization of TCM (2224). In addition, the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP database; http://tcmspw.com/tcmsp.php) was used to supplement active components. The TCMSP database integrated active components, relevant diseases, targets, and pharmacokinetic data of drugs, providing a new platform for studying the mechanism of drug action systematically (25). Only components with antiviral or anti-inflammatory effects were retained for later studies.

2.2 Ligand preparation and the prediction of absorption, distribution, metabolism, excretion, and toxicity properties

The Prepare Ligands protocol helped to prepare ligands for input components, performing tasks such as removing duplicates, enumerating isomers and tautomers. This study performed the following steps to complete this operation: changing ionization, generating tautomers, generating isomers, and fixing bad valencies. Then, the ligands of active components needed to be minimized in batches by Minimize Ligands protocol before ADMET properties’ prediction. ADMET refers to the Absorption, Distribution, Metabolism, Excretion, and Toxicity properties of a molecule within an organism (26, 27). The ADMET properties predicted in this study were hepatotoxicity, Blood-brain barrier penetration (BBB) and Human intestinal absorption (HIA) (28, 29). Optimizing these two properties during early drug discovery was crucial for reducing ADMET problems later in development.

2.3 The prediction of toxicological properties and druggability screening

Toxicity Prediction by Komputer Assisted Technology (TOPKAT) accurately and rapidly assessed the toxicity of chemicals based solely on their 2D molecular structure. It could assess the toxicological properties of candidate active components with a range of robust, cross-validated, and Quantitative Structure-Toxicity Relationship (QSTR) models (30). The toxicological properties we predicted in this study were the Ames test, Rodent Carcinogenicity, Aerobic Biodegradability, and oral LD50 in rats. After the predicted results were obtained, all active components that exceed these four properties’ optimal prediction space (OPS) needed to be deleted manually. In order to exclude active components with poor absorption, permeation, and oral bioavailability, it was necessary to ensure that the screened active components comply with Lipinski’s rule of five (31) and Veber’s rules (32, 33). The active components that did not meet these rules will be automatically deleted at the end of the calculation. The reserved active components had better pharmacokinetic properties and higher bioavailability in the metabolism of organisms.

2.4 Performing reverse finding target

The technique of reverse finding target was the core of this study. Reverse finding target process was to match the pharmacophore models with active components which had high credibility after a series of screening. In addition, the matching degree of pharmacophore models and active components can be distinguished by different colors in the “Heat map of Ligand profiler”. Generally, the higher the matching between the pharmacophore models and the active components, the higher the confidence of the targets corresponding to the pharmacophore models. Based on these pharmacophore models, we can identify the target proteins regulated by the active components of QFPD. We then used the search function in the Protein Data Bank (PDB) database to convert the target protein names to standard gene names. COVID-19 targets recorded in the Genecards database and QFPD targets regulated by active ingredients in QFPD were compared to get common targets. These common targets represented potential targets for QFPD to exert anti-SARS-CoV-2 or anti-inflammatory effects.

2.5 Construction of protein-protein interaction network

The interaction between the targets was illustrated as a PPI network. The construction of the PPI network was realized via the Search Tool for the Retrieval of Interacting Genes (STRING; https://string-db.org/). It gathered a large number of information resources, mainly for storing PPI data identified by experiments, calculating predicted data, and collecting public text (34).

2.6 Construction of “herb-active component-target” interaction network diagram

The “herb-active component-target” interaction network was plotted by the major constituents of QFPD and their targets using Cytoscape 3.8.0. The network constructed by this information was represented as nodes and edges with related data attributes, which revealed the close relationship between diseases, targets, and drugs, and provided ideas for further study of multi-target and multi-component TCM formula.

2.7 Pathway analysis of QFPD

Gene set enrichment analysis (GSEA) was performed on transcriptome sequencing data of COVID-19 from Gene Expression Omnibus (GEO) database using GSEA 4.1.0. The COVID-19 group consisted of 30 samples, which were organized into gene expression matrix. Based on the expression of the target, they were divided into target high expression and low expression groups for GSEA analysis.

The potential targets of QFPD were submitted to DAVID (https://david.ncifcrf.gov/) to analyze Gene Ontology (GO) function enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. GO analysis was involved in terms of cellular component (CC), molecular function (MF), as well as biological process (BP) (35). CC was defined as the active sites of gene products in cells. MF was considered as the biochemical activity. BP involved the contribution of genes or genetic products to biological objectives. KEGG was a highly integrated database for biological interpretation of wholly sequenced genomes through pathway mapping (36).

3 Results and discussion

3.1 Screening the active components in QFPD from the database

A total of 108 active components in QFPD were selected from TCMdb and TCMSP database based on the above criteria about antiviral or anti-inflammatory effects. The basic information of 108 active components was showed in Table 1.

Table 1

HerbActive componentsEffectReferences
HuangqinIsoscutellareinantiviral(37, 38)
Baicaleinanti-inflammatory
Baicalinanti-inflammatory
Eriodictyolanti-inflammatory
Oroxylin Aanti-inflammatory
beta-Sitosterolanti-inflammatory
Wogoninanti-inflammatory
Wogonosideanti-inflammatory
Chrysinanti-inflammatory, antiviral
Jiangbanxiabeta-Sitosterolanti-inflammatory(39)
KuandonghuaGallic acidanti-inflammatory(4042)
Hyperinanti-inflammatory
Rutinanti-inflammatory, antiviral
SheganTectoridinanti-inflammatory(43, 44)
Tectorigeninanti-inflammatory
Mangiferinanti-inflammatory, antiviral
XixinSesaminantiviral(4547)
Aristolochic acidantiviral
(+)-Eudesma-4(15),7(11)-dien-8-oneanti-inflammatory
Terpinen-4-olanti-inflammatory
Shanyaobeta-Sitosterolanti-inflammatory(39)
ZhishiTangeretinantiviral(48, 49)
5,7,4'-Trimethoxyflavoneantiviral
Hesperidinantiviral
Apigenin-7-O-neohesperidosideantiviral
Lonicerinanti-inflammatory
Naringinanti-inflammatory, antiviral
ChenpiHesperidinantiviral(49, 50)
Naringinanti-inflammatory, antiviral
HuoxiangLinaloolantiviral(5153)
Pachypodolantiviral
Acacetinanti-inflammatory
Friedelan-3-oneanti-inflammatory
beta-Pineneanti-inflammatory
beta-Sitosterolanti-inflammatory
Cinnamaldehydeanti-inflammatory
MahuangKaempferolantiviral(54, 55)
(4S,5R) Ephedroxaneanti-inflammatory
Isoquercitrinanti-inflammatory
N-Methylephedrineanti-inflammatory
ShengjiangLinaloolantiviral(45, 51, 56)
6-Dehydrogingerdioneanti-inflammatory
10-Dehydrogingerdioneanti-inflammatory
Geraniolanti-inflammatory
D-Isoborneolanti-inflammatory
L-Isoborneolanti-inflammatory
Terpinen-4-olanti-inflammatory
XingrenLinaloolantiviral(51, 57)
Dihydroquercetinanti-inflammatory
Eriodictyolanti-inflammatory
ZiwanQuercetinantiviral(58, 59)
Friedelan-3-oneanti-inflammatory
Anetholeanti-inflammatory
BaizhuAtractylenolide Ianti-inflammatory(60)
Atractyloneanti-inflammatory
(+)-Eudesma-4(15),7(11)-dien-8-oneanti-inflammatory
FulingDihydroquercetinanti-inflammatory(61, 62)
Astilbinanti-inflammatory, antiviral
Guizhi2-Methoxycinnamaldehydeanti-inflammatory(39, 63)
beta-Sitosterolanti-inflammatory
Cinnamaldehydeanti-inflammatory, antiviral
ZhulingMANanti-inflammatory, antiviral(64)
GLAanti-inflammatory, antiviral
ZexieEmodinanti-inflammatory, antiviral(6567)
HMFanti-inflammatory, antiviral
alpha-D-fructofuranoseanti-inflammatory, antiviral
EA-fructofuranosideanti-inflammatory, antiviral
stachyoseanti-inflammatory, antiviral
NCAanti-inflammatory, antiviral
1-Monolinoleinanti-inflammatory, antiviral
stearic acidanti-inflammatory, antiviral
orientalolfanti-inflammatory, antiviral
Sulfoorientalol Canti-inflammatory, antiviral
raffinoseanti-inflammatory, antiviral
(2R,3S,4S,5R)-2-ethoxy-2,5-bis(hydroxymethyl)oxolane-3,4-diolanti-inflammatory, antiviral
Zhigancao3,3'-Dimethylquercetinantiviral(11, 39, 41, 6870)
Glycycoumarinantiviral
Glepidotin Dantiviral
Glycyrrhisoflavoneantiviral
Glycyrrhizic acidantiviral
Isolicoflavonolantiviral
Licopyranocoumarinantiviral
6,8-Bis(C-beta-glucosyl)-apigeninanti-inflammatory
Isoliquiritinanti-inflammatory
Isoquercitrinanti-inflammatory
Liquiritic acidanti-inflammatory
Pinocembrinanti-inflammatory
beta-Sitosterolanti-inflammatory
Glycyrrhetinic acidanti-inflammatory
Licochalcone Aanti-inflammatory, antiviral
Glycyrrhizic acidanti-inflammatory, antiviral
Rutinanti-inflammatory, antiviral
ChaihuLinaloolantiviral(51, 56, 7173)
Saikosaponin Cantiviral
Geraniolanti-inflammatory
Isoquercitrinanti-inflammatory
Kaempferitrinanti-inflammatory
Oroxylin Aanti-inflammatory
Propapyriogenin A2anti-inflammatory
Pulegoneanti-inflammatory
Saikosaponin B2anti-inflammatory
Scoparoneanti-inflammatory
alpha-Spinasterolanti-inflammatory
Wogoninanti-inflammatory
Saikosaponin Danti-inflammatory, antiviral
Saikosaponin Aanti-inflammatory, antiviral
(E)-3-(3,4-Dimethoxyphenyl)-2-propen-1-yl (Z)-2-[(Z)-2-methyl-2-butenoyloxymethyl] butenoateanti-inflammatory
1-(3,4,5-Trimethoxyphenyl)-2-propenyl 2-(2-methyl-2Z-butenoyloxymethyl)-2Z-butenoateanti-inflammatory

Active components in QFPD.

3.2 Ligand preparation and prediction of ADMET properties

Prepare Ligands and Minimize Ligands protocols in DS2020 were used to prepare and minimize the structures of 108 active components, respectively. The results showed that 107 tautomers were produced during the preparation process, so the number of active components reached 215. After minimization, the number of active components remained unchanged. Favorable ADMET properties can be considered as essential nature for a candidate drug. As shown in Figure 1, the green ellipse represents 99% of the absorption confidence interval, and the blue ellipse represents 99% of the BBB confidence interval. In general, the absorption outside the 99% ellipse tends to drop relatively quickly. If the active component is outside the 99% confidence interval of the BBB model, the prediction of the molecule is considered unreliable. In order to reduce the risk of late-stage attrition, we excluded active components outside the 99% confidence interval of the BBB model and HIA model. In this process, all the active components from the 5 herbs (Jiangbanxia, Chenpi, Fuling, Shanyao, Zhuling) were excluded. In the end, only 97 compounds from 15 herbs were left.

Figure 1

3.3 TOPKAT and druggability screening

We checked whether the 97 active components were in the OPS of four toxicological properties (Ames test, Rodent Carcinogenicity, Aerobic Biodegradability, and oral LD50). It can be seen from Table S1 that the number of candidate active components became 68 after excluding active components that did not meet the OPS. Due to the unsatisfactory results of the active components of Kuandonghua and Ziwan, they should not be further studied. In the process of druggability screening, the program automatically eliminated 2 unqualified active components according to Lipinski’s rule of five and Veber’s rules. Therefore, 66 active components from 13 herbs may become oral drugs.

3.4 Reverse finding target

The results showed that the corresponding targets of active components in Guizhi did not have antiviral or anti-inflammatory effects. Therefore, 64 active components from 12 herbs were retained in the reverse finding target process. The structures of 64 active components are shown in Figure S1. It can be seen from Figure 2 that the horizontal axis and the longitudinal axis represent the pharmacophore models and the active components, respectively. The color gradient trend is red, yellow, green, and blue on the Heat map. The pharmacophore models with high and low Fit Value are represented by red and blue, respectively. Red means that the matching degree is good. Based on these pharmacophore models, we found that the possible targets of the 64 active components in QFPD were Antigen peptide transporter 1 (TAP1), Retinol-binding protein 4 (RBP4), Interleukin 1 receptor antagonist (IL1RN), Centromere-associated protein E (CENPE), Beta-secretase 1 (BACE1), Transthyretin (TTR), Tyrosine-protein kinase Fyn (FYN), Thyroid hormone receptor alpha (THRA), Pulmonary surfactant-associated protein D (SFTPD), Nuclear receptor subfamily 0 group B member 2 (NR0B2), Cellular tumor antigen p53 (TP53), SRSF protein kinase 1 (SRPK1), RAC-alpha serine/threonine-protein kinase (AKT1) and Protein Mdm4 (MDM4). We compared 14 targets regulated by 64 active components in QFPD with the COVID-19 targets recorded in Genecards databases and found the common targets RBP4 (74), IL1RN (8), TTR (75), FYN (76), SFTPD (77), TP53 (78), SRPK1 (79), and AKT1 (80). The information of 8 potential targets is shown in Table 2. FYN, AKT1, SFTPD, SRPK1, and TP53 were SARS-CoV-2 specific targets.

Figure 2

Table 2

PharmacophorePossible target(gene name)EffectReferences
1rbp-02,1rbp-02-s,1rbp-03,1rbp-03-s,1rbp-04,1rbp-04-s,1rbp-05,1rbp-06,1rbp-07-s,1rbp-08,1rbp-08-s,1rbp-09,1rbp-10,1rbp-10-s1rbp(RBP4)anti-inflammatory(74)
1sri-01-s, 1sri-02-s, 1sri-03-s, 1sri-04-s, 1sri-05-s, 1sri-06-s, 1sri-07-s, 1sri-08-s, 1sri-09-s, 1sri-10-s1sri(IL1RN)anti-inflammatory(8)
1tyr-01,1tyr-01-s,1tyr-02,1tyr-02-s,1tyr-03,1tyr-03-s,1tyr-04,1tyr-04-s,1tyr-05,1tyr-05-s,1tyr-06,1tyr-07,1tyr-07-s,1tyr-08,1tyr-08-s,1tyr-09,1tyr-09-s,1tyr-10,1tyr-10-s1tyr(TTR)anti-inflammatory(75)
2dq7-01,2dq7-02,2dq7-02-s,2dq7-03,2dq7-03-s,2dq7-04,2dq7-05,2dq7-05-s,2dq7-06,2dq7-06-s,2dq7-07,2dq7-07-s,2dq7-08,2dq7-09,2dq7-09-s,2dq7-102dq7(FYN)anti-SARS-CoV-2
anti-inflammatory
(76)
3cqu-01,3cqu-01-s,3cqu-02,3cqu-02-s,3cqu-03,3cqu-03-s,3cqu-04,3cqu-04-s,3cqu-05,3cqu-05-s,3cqu-06,3cqu-06-s,3cqu-07,3cqu-07-s,3cqu-08,3cqu-08-s,3cqu-09,3cqu-09-s,3cqu-10,3cqu-10-s3cqu(AKT1)anti-SARS-CoV-2
anti-inflammatory
(80)
3cqw-01,3cqw-01-s,3cqw-02,3cqw-03, 3cqw-04, 3cqw-04-s, 3cqw-05, 3cqw-05-s, 3cqw-06, 3cqw-06-s, 3cqw-07, 3cqw-07-s, 3cqw-08, 3cqw-09, 3cqw-10, 3cqw-10-s3cqw(AKT1)anti-SARS-CoV-2
anti-inflammatory
(80)
2orj-01,2orj-02,2orj-03,2orj-042orj(SFTPD)anti-SARS-CoV-2
anti-inflammatory
(77)
2x0u-01,2x0u-01-s2x0u(TP53)anti-SARS-CoV-2
anti-inflammatory
(78)
2x0v-01,2x0v-01-s2x0v(TP53)anti-SARS-CoV-2
anti-inflammatory
(78)
3beg-01,3beg-023beg(SRPK1)anti-SARS-CoV-2(79)

All pharmacophores and their possible corresponding targets obtained by reverse finding target.

3.5 Construction of protein-protein interaction network

PPI network was constructed by String with the potential targets of the 62 active components in QFPD. It can be seen from Figure 3A that the network contained 8 nodes and 6 edges. The nodes represented the targets, and the edges represented the interactions between the targets. The more edges the node had, the more critical it was in the network. TP53 and AKT1, with a high degree of connectivity, were core genes that may play an essential role in treating COVID-19 with QFPD. The network in Figure 3B contained 5 nodes and 5 edges. If medium confidence≧0.4 was selected as the screening criteria, the candidate targets were TP53, AKT1, FYN, and SRPK1. If the highest confidence≧0.9 was selected as the screening criteria, the candidate targets were TP53, AKT1. The network in Figure 3C contained 7 nodes and 4 edges. If medium confidence≧0.4 was selected as the screening criteria, the candidate targets were TP53, AKT1, RBP4, TTR, and FYN. If the highest confidence≧0.9 was selected as the screening criteria, the candidate targets were TP53, AKT1, RBP4, and TTR.

Figure 3

3.6 Construction of “herb-active component-target” interaction network diagram

As shown in Figure 4, 62 active components from 12 herbs (Mahuang, Zhishi, Huoxiang, Zexie, Shegan, Shengjiang, Chaihu, Huangqin, Xingren, Baizhu, Xixin, and Zhigancao) have anti-SARS-CoV-2 or anti-inflammatory effects. Among them, Eriodictyol was common in Xixin and Huangqin. Wogonin was common in Chaihu and Huangqin. Geraniol was common in Chaihu and Shengjiang. (+)-Eudesma-4(15),7(11)-dien-8-one was common in Xixin and Baizhu. It can be seen from Table 3 that, Kaempferol2, Kaempferol3, Emodin7, and Isolicoflavonol3 only had anti-SARS-CoV-2 effects, (4S_5R) Ephedroxane and Pulegone only had anti-inflammatory effects. The other 56 components were both anti-inflammatory and anti-SARS-CoV-2. Among these components, Quercetin, Wogonin, and Emodin were able to interfere with various stages of the coronavirus entry and replication cycle (59, 81, 82). Kaempferol could be used as an antiviral drug against the 3a Channel Protein of Coronavirus (55). Baicalein had a high affinity for SARS-CoV-2 3CLpro (83). They were identified as candidate active components for COVID-19. In addition, each target was bound to two or more active components, indicating that these targets could be affected by multiple active components simultaneously to exert different effects.

Figure 4

Table 3

Active componentsEffect
Kaempferol3anti-SARS-CoV-2
Emodin7anti-SARS-CoV-2
Kaempferol2anti-SARS-CoV-2
Isolicoflavonol3anti-SARS-CoV-2
(4S_5R)_Ephedroxaneanti-inflammatory
Pulegoneanti-inflammatory
Pachypodolanti-SARS-CoV-2, anti-inflammatory
3_3_-Dimethylquercetin1anti-SARS-CoV-2, anti-inflammatory
Glycyrrhisoflavoneanti-SARS-CoV-2, anti-inflammatory
Oroxylin_A2anti-SARS-CoV-2, anti-inflammatory
Wogonin1anti-SARS-CoV-2, anti-inflammatory
Isolicoflavonol2anti-SARS-CoV-2, anti-inflammatory
6-Dehydrogingerdioneanti-SARS-CoV-2, anti-inflammatory
Isolicoflavonol1anti-SARS-CoV-2, anti-inflammatory
3_3_-Dimethylquercetin3anti-SARS-CoV-2, anti-inflammatory
Baicalein2anti-SARS-CoV-2, anti-inflammatory
3_3_-Dimethylquercetin4anti-SARS-CoV-2, anti-inflammatory
Emodin3anti-SARS-CoV-2, anti-inflammatory
Emodin1anti-SARS-CoV-2, anti-inflammatory
Wogonin2anti-SARS-CoV-2, anti-inflammatory
Pinocembrin3anti-SARS-CoV-2, anti-inflammatory
Glycycoumarin2anti-SARS-CoV-2, anti-inflammatory
3_3_-Dimethylquercetin2anti-SARS-CoV-2, anti-inflammatory
Eriodictyol2anti-SARS-CoV-2, anti-inflammatory
Tangeretinanti-SARS-CoV-2 anti-inflammatory
Aristolochic_acidanti-SARS-CoV-2, anti-inflammatory
(+)-Eudesma-4(15)_7(11)-dien-8-oneanti-SARS-CoV-2, anti-inflammatory
Glycycoumarin1anti-SARS-CoV-2, anti-inflammatory
5_7_4_-Trimethoxyflavoneanti-SARS-CoV-2, anti-inflammatory
Glycyrrhetinic_acidanti-SARS-CoV-2, anti-inflammatory
Geraniolanti-SARS-CoV-2, anti-inflammatory
Licopyranocoumarinanti-SARS-CoV-2, anti-inflammatory
Propapyriogenin_A2anti-SARS-CoV-2, anti-inflammatory
Pinocembrin2anti-SARS-CoV-2, anti-inflammatory
Isoscutellarein3anti-SARS-CoV-2, anti-inflammatory
Liquiritic_acidanti-SARS-CoV-2, anti-inflammatory
Sulfoorientalol_Canti-SARS-CoV-2 anti-inflammatory
Eriodictyol1anti-SARS-CoV-2, anti-inflammatory
Emodin2anti-SARS-CoV-2, anti-inflammatory
Tectorigenin2anti-SARS-CoV-2, anti-inflammatory
Emodin4anti-SARS-CoV-2, anti-inflammatory
Pinocembrin5anti-SARS-CoV-2, anti-inflammatory
Chrysin3anti-SARS-CoV-2, anti-inflammatory
Eriodictyol4anti-SARS-CoV-2, anti-inflammatory
Baicalein1anti-SARS-CoV-2, anti-inflammatory
Isoscutellarein1anti-SARS-CoV-2, anti-inflammatory
Isoscutellarein2anti-SARS-CoV-2, anti-inflammatory
Eriodictyol3anti-SARS-CoV-2, anti-inflammatory
Kaempferol1anti-SARS-CoV-2 anti-inflammatory
Chrysin1anti-SARS-CoV-2, anti-inflammatory
Chrysin2anti-SARS-CoV-2, anti-inflammatory
Pinocembrin1anti-SARS-CoV-2, anti-inflammatory
Pinocembrin4anti-SARS-CoV-2, anti-inflammatory
3_3_-Dimethylquercetin5anti-SARS-CoV-2, anti-inflammatory
HMFanti-SARS-CoV-2, anti-inflammatory
Oroxylin_A1anti-SARS-CoV-2, anti-inflammatory
Tectorigenin3anti-SARS-CoV-2, anti-inflammatory
Tectorigenin1anti-SARS-CoV-2, anti-inflammatory
NCAanti-SARS-CoV-2, anti-inflammatory
Emodin5anti-SARS-CoV-2, anti-inflammatory
Emodin6anti-SARS-CoV-2, anti-inflammatory
Scoparoneanti-SARS-CoV-2, anti-inflammatory

62 components determined by multiple computational processes in QFPD.

3.7 Pathway analysis of QFPD

We identified TP53 and AKT1 as core targets based on the PPI network. Therefore, according to the expression of TP53 or AKT1, we divided them into high and low expression groups for GSEA analysis. P-value<0.05 was considered statistically significant. Figure 5A showed that 6 significant pathways were enriched in the TP53 high expression group: RNA polymerase, primary immunodeficiency, intestinal immune network for IGA production, systemic lupus erythematosus, allograft rejection, and autoimmune thyroid disease. 3 pathways were enriched in the TP53 low expression group: O glycan biosynthesis, regulation of autophagy, and long-term potentiation. 20 meaningful pathways were enriched in the AKT1 high expression group. We showed the first six significant enrichments in Figure 5B, which were taste transduction, ECM receptor interaction, focal adhesion, ABC transporters, long term depression, and linoleic acid metabolism. 3 pathways were enriched in the AKT1 low expression group, namely other glycan degradation, glycosylphosphatidylinositol GPI anchor biosynthesis, peroxisome, and hematopoietic cell lineage.

Figure 5

It can be seen from Table 4 that 8 potential targets of QFPD (RBP4, IL1RN, TTR, FYN, SFTPD, TP53, SRPK1, and AKT1) were mainly enriched in 21 BP entries. 17 BP entries were determined with P-value<0.05 (Figure 6). The core BP entries mainly included the viral process, intracellular signal transduction, innate immune response, protein phosphorylation, and cell differentiation. During SARS-CoV-2 infection, the innate immune system experienced substantial disturbance (84). Several of the cytokines involved in the reaction employ a distinct intracellular signaling pathway mediated by Janus kinases (85). Researchers studied the perturbation in protein phosphorylation during SARS-CoV-2 infection by mass spectrometry, and the results showed that large changes were observed in protein phosphorylation (86). This evidences verified that QFPD regulates diseases through a variety of biological processes. The core MF entries mainly included protein binding, identical protein binding, enzyme binding, and ATP binding. A recent study reported that SARS-CoV-2 enters the host cells through the binding of its spike protein to the cell surface-expressing angiotensin-converting enzyme 2 (ACE2) (87). Therefore, inhibiting the binding of some specific proteins or enzymes may attenuate the progression of COVID-19. The core CC entries mainly included protein complex and extracellular space. The GO analysis results showed that AKT1, FYN, TP53, TTR, and RBP4 were key targets involved in regulation. The KEGG analysis results showed that AKT1, FYN, and TP53 were key targets involved in regulation (Table 5). The top 13 KEGG pathways are shown in Figure 7. The core pathways mainly included Sphingolipid signaling pathway, Fc epsilon RI signaling pathway, Apoptosis, and Measles. Sphingolipids play a vital role in protecting the lung from damages (88). The Fc epsilon RI signaling pathway is associated with cytokine secretion and inflammatory responses (89). Based on previous data, SARS-CoV-2 may have the ability to induce endogenous and exogenous apoptotic pathways and stimulate T cell apoptosis (90). Therefore, we speculate that the active components in QFPD may play an important role in the therapeutic of COVID-19 by multiple pathways.

Table 4

ItemCountP-valueGenes
BPviral process30.0063FYN, TP53, SRPK1
intracellular signal transduction30.0111AKT1, FYN, SRPK1
innate immune response30.0126SFTPD, FYN, SRPK1
protein phosphorylation30.0141AKT1, FYN, SRPK1
cell differentiation30.0145AKT1, FYN, TP53
positive regulation of protein localization to nucleus20.0087AKT1, FYN
retinol metabolic process20.0124RBP4, TTR
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand20.0153AKT1, FYN
retinoid metabolic process20.0252RBP4, TTR
regulation of phosphatidylinositol 3-kinase signaling20.0321AKT1, FYN
T cell costimulation20.0321AKT1, FYN
cellular response to hypoxia20.0393AKT1, TP53
glucose homeostasis20.0414RBP4, AKT1
response to ethanol20.0430RBP4, FYN
phosphatidylinositol-mediated signaling20.0434AKT1, FYN
platelet activation20.0470AKT1, FYN
cellular protein metabolic process20.0482TTR, SFTPD
regulation of signal transduction by p53 class mediator20.0506AKT1, TP53
negative regulation of gene expression20.0557AKT1, FYN
cellular response to DNA damage stimulus20.0836AKT1, TP53
regulation of apoptotic process20.0855FYN, TP53
MFprotein binding80.0103IL1RN, RBP4, TTR, SFTPD, AKT1, FYN, TP53, SRPK1
identical protein binding40.0027TTR, AKT1, FYN, TP53
ATP binding40.0185AKT1, FYN, TP53, SRPK1
enzyme binding30.0076AKT1, FYN, TP53
protein heterodimerization activity30.0145RBP4, TTR, TP53
protein phosphatase 2A binding20.0111AKT1, TP53
CCprotein complex40.0004RBP4, TTR, AKT1, TP53
extracellular space40.0112IL1RN, RBP4, TTR, SFTPD
mitochondrion30.0875AKT1, FYN, TP53
nuclear matrix20.0367TP53, SRPK1

BP, MF and CC entries of GO analysis.

Figure 6

Table 5

PathwayCountP-valueGenes
Sphingolipid signaling pathway30.0018AKT1, FYN, TP53
Measles30.0022AKT1, FYN, TP53
Endometrial cancer20.0299AKT1, TP53
Non-small cell lung cancer20.0322AKT1, TP53
Colorectal cancer20.0356AKT1, TP53
Apoptosis20.0356AKT1, TP53
Central carbon metabolism in cancer20.0367AKT1, TP53
Glioma20.0373AKT1, TP53
Pancreatic cancer20.0373AKT1, TP53
Fc epsilon RI signaling pathway20.0390AKT1, FYN
Melanoma20.0407AKT1, TP53
Chronic myeloid leukemia20.0412AKT1, TP53
Small cell lung cancer20.0485AKT1, TP53

13 KEGG pathways.

Figure 7

Conclusion

In this study, we used various network pharmacology methods combined with CADD techniques to reveal the diversity of potential targets and therapeutic pathways for QFPD against COVID-19. We found that RBP4, IL1RN, TTR, FYN, SFTPD, TP53, SRPK1, and AKT1 are highly related to COVID-19. QFPD could act on multiple pathways, including viral process, immunodeficiency, RNA polymerase, Sphingolipid signaling pathway, and taste transduction. The results showed that QFPD has “multi-component, multi-target, and multi-pathway” characteristics in regulating inflammation, viral infection, cellular damage, and immune responses. Our work helps to establish the basic theory of TCM for the treatment of COVID-19.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Author contributions

ZW conducted the literature review, designed the research system, collated data information, and wrote the manuscript. JZ contributed to the manuscript's revision and guided the calculation procee. HG contributed to the conception and design of the study. All authors participate in the revision, reading, and approval the submitted version.

Funding

This work was financially supported by the High-end Talent Team Construction Foundation [Grant No. 108-10000318], the Cooperation Project of University and Local Enterprise in Yantai of Shandong Province (2021XDRHXMXK23).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1015271/full#supplementary-material

References

  • 1

    PinottiFDi DomenicoLOrtegaEMancastroppaMPullanoGValdanoEet al. Tracing and analysis of 288 early SARS-CoV-2 infections outside China: A modeling study. PloS Med (2020) 17:10031931003193. doi: 10.1371/journal.pmed.1003193

  • 2

    LarremoreDBToomreDParkerR. Modeling the effectiveness of olfactory testing to limit SARS-CoV-2 transmission. Nat Commun (2021) 12:3664–4. doi: 10.1038/s41467-021-23315-5

  • 3

    LowerySASariolAPerlmanS. Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. Cell Host Microbe (2021) 29:1052–62. doi: 10.1016/j.chom.2021.05.004

  • 4

    Amat-SantosIJSantos-MartinezSLópez-OteroDNombela-FrancoLGutiérrez-IbanesEDel ValleRet al. Ramipril in high-risk patients with COVID-19. J Am Coll Cardiol (2020) 76:268–76. doi: 10.1016/j.jacc.2020.05.040

  • 5

    LiYLiuXGuoLLiJZhongDZhangYet al. Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis. Systematic Rev (2020) 9:75–5. doi: 10.1186/s13643-020-01343-4

  • 6

    ConstantinosGAnnaHDimitriosKTaxiarchisPVasilikiT. Status of traditional Chinese medicine in Greece and its approach on COVID-19 pandemic. Chin Med Culture (2021) 4:7885. doi: 10.4103/CMAC.CMAC_16_21

  • 7

    LiMYangYLiuYZhengMLiJChenLet al. Progress of traditional Chinese medicine treating COVID-19. World J Traditional Chin Med (2021) 7:167–83. doi: 10.4103/wjtcm.wjtcm_68_20

  • 8

    Fricke-GalindoIFalfan-ValenciaR. Genetics insight for COVID-19 susceptibility and severity: a review. Front Immunol (2021) 12:1057–8. doi: 10.3389/fimmu.2021.622176

  • 9

    Huan−HuanTQiLPan−HongJXiang−DongZ. Clinical value of related inflammatory factors in COVID⁃19. J Hainan Med Univ (2021) 27:647–50. doi: 10.13210/j.cnki.jhmu.20210329.001

  • 10

    VannucchiAMSordiBMorettiniANozzoliCPoggesiLPieralliFet al. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia (2021) 35:1121–33. doi: 10.1038/s41375-020-01018-y

  • 11

    WangZZhangJZhanJGaoH. Screening out anti-inflammatory or anti-viral targets in xuanfei baidu tang through a new technique of reverse finding target. Bioorganic Chem (2021) 116:105274–4. doi: 10.1016/j.bioorg.2021.105274

  • 12

    ShiNLiuBLiangNMaYGeYYiHet al. Association between early treatment with qingfei paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study. Pharmacol Res (2020) 161:105290–0. doi: 10.1016/j.phrs.2020.105290

  • 13

    XinSChengXZhuBLiaoXYangFSongLet al. Clinical retrospective study on the efficacy of qingfei paidu decoction combined with Western medicine for COVID-19 treatment. Biomed Pharmacother (2020) 129:110500–0. doi: 10.1016/j.biopha.2020.110500

  • 14

    RenWMaYWangRLiangPSunQPuQet al. Research advance on qingfei paidu decoction in prescription principle, mechanism analysis and clinical application. Front Pharmacol (2021) 11:2046–6. doi: 10.3389/fphar.2020.589714

  • 15

    GaoKSongYPChenHZhaoLTMaL. Therapeutic efficacy of qingfei paidu decoction combined with antiviral drugs in the treatment of corona virus disease 2019: A protocol for systematic review and meta analysis. Medicine (2020) 99:20489–9. doi: 10.1097/MD.0000000000020489

  • 16

    JunhuaMYangHQianCQiangGYonggangCJingA. A retrospective study on the treatment of COVID-19 type common/type severe with qingfei paidu decoction. Chin J Hosp Pharm (2020) 40:2152–7. doi: 10.3969/j.issn.2097-0005.2021.12.009

  • 17

    SilvaC.H.T.D.P.D.SilvaVResendeJRodriguesPFBononiFCBenevenutoCGet al. Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy. J Mol Graphics Model (2010) 28:513–23. doi: 10.1016/j.jmgm.2009.11.011

  • 18

    ZhangAHuiSYangBWangX. Predicting new molecular targets for rhein using network pharmacology. BMC Syst Biol (2012) 6:20–0. doi: 10.1186/1752-0509-6-20

  • 19

    ShaoLZhangB. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Natural Medicines (2013) 11:110–20. doi: 10.1016/S1875-5364(13)60037-0

  • 20

    Chang-XiaoLLiuRFanH-RNgX-FXiaoX-PChen. Network pharmacology bridges traditional application and modern development of traditional Chinese medicine. Chin Herbal Medicines (2015) 7:317. doi: 10.1016/S1674-6384(15)60014-4

  • 21

    YangYDingZWangYZhongRFengYXiaTet al. Systems pharmacology reveals the mechanism of activity of physalis alkekengi l. var. franchetii against lipopolysaccharide-induced acute lung injury. J Cell Mol Med (2020) 24:5039–56. doi: 10.1111/jcmm.15126

  • 22

    LiuYSunY. China Traditional Chinese medicine (TCM) patent database. World Patent Inf (2004) 26:91–6. doi: 10.1016/S0172-2190(03)00110-8

  • 23

    Hsin-YiC. Discovery of novel insomnia leads from screening traditional Chinese medicine database. J Biomolecular Structure Dynamics (2013) 32:776–91. doi: 10.1080/07391102.2013.790849

  • 24

    AryaHCoumarMS. Virtual screening of traditional Chinese medicine (TCM) database: identification of fragment-like lead molecules for filariasis target asparaginyl-tRNA synthetase. J Mol Modeling (2014) 20:2266–7. doi: 10.1007/s00894-014-2266-9

  • 25

    RuJLiPWangJZhouWLiBHuangCet al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform (2014) 6:13–4. doi: 10.1186/1758-2946-6-13

  • 26

    MaLYZhouQLYangXBWangHPYangXW. Metabolism of 20(S)-ginsenoside Rg2 by rat liver microsomes: Bioactivation to SIRT1-activating metabolites. Molecules (2016) 21:757–8. doi: 10.3390/molecules21060757

  • 27

    TailongLYouyongLiYunlongSDanLiHuiyongSun. ADMET evaluation in drug discovery: 15. accurate prediction of rat oral acute toxicity using relevance vector machine and consensus modeling. J Cheminformatics (2016) 8:68. doi: 10.1186/s13321-016-0117-7

  • 28

    QidwaiT. QSAR modeling, docking and ADMET studies for exploration of potential anti-malarial compounds against plasmodium falciparum. In Silico Pharmacol (2017) 5:67. doi: 10.1007/s40203-017-0026-0

  • 29

    AlamSKhanF. Virtual screening, docking, ADMET and system pharmacology studies on garcinia caged xanthone derivatives for anticancer activity. Sci Rep (2018) 8:5524–5. doi: 10.1038/s41598-018-23768-7

  • 30

    RuizPBegluittiGTincherTWheelerJMumtazM. Prediction of acute mammalian toxicity using QSAR methods: a case study of sulfur mustard and its breakdown products. Molecules (Basel Switzerland) (2012) 17:89829001. doi: 10.3390/molecules17088982

  • 31

    Bahadur GurungAAjmal AliMLeeJAbul FarahMMashay Al-AnaziK. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme. J King Saud University. Sci (2020) 32:2845–53. doi: 10.1016/j.jksus.2020.07.007

  • 32

    AlamSKhanF. 3D-QSAR, docking, ADME/Tox studies on flavone analogs reveal anticancer activity through tankyrase inhibition. Sci Rep (2019) 9:5414–4. doi: 10.1038/s41598-019-41984-7

  • 33

    ZhouYLuXYangHChenYWangFLiJet al. Discovery of selective butyrylcholinesterase (BChE) inhibitors through a combination of computational studies and biological evaluations. Molecules (Basel Switzerland) (2019) 24:4217–7. doi: 10.3390/molecules24234217

  • 34

    DamianSAndreaFStefanWKristofferFDavideHJaimeHCet al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res (2015) 43:447–52. doi: 10.1093/nar/gku1003

  • 35

    GrindrodPKibbleM. Review of uses of network and graph theory concepts within proteomics. Expert Rev Proteomics (2004) 1:229–38. doi: 10.1586/14789450.1.2.229

  • 36

    KanehisaMGotoSSatoYFurumichiMTanabeM. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res (2012) 40:D109–14. doi: 10.1093/nar/gkr988

  • 37

    ShenY-CChiouW-FChouY-CChenC-F. Mechanisms in mediating the anti-inflammatory effects of baicalin and baicalein in human leukocytes. Eur J Pharmacol (2003) 465:171–81. doi: 10.1016/S0014-2999(03)01378-5

  • 38

    LeeJYParkW. Anti-inflammatory effects of oroxylin a on RAW 264.7 mouse macrophages induced with polyinosinic-polycytidylic acid. Exp Ther Med (2016) 12:151–6. doi: 10.3892/etm.2016.3320

  • 39

    Paniagua-PérezRFlores-MondragónGReyes-LegorretaCHerrera-LópezBCervantes-HernándezIMadrigal-SantillánOet al. Evaluation of the anti-inflammatory capacity of beta-sitosterol in rodent assays. Afr J Traditional Complementary Altern Medicines (2017) 14:123–30. doi: 10.21010/ajtcam.v14i1.13

  • 40

    KroesBVVan Den BergAVan UffordHQVan DijkHLabadieR. Anti-inflammatory activity of gallic acid. Planta Med (1992) 58:499504. doi: 10.1055/s-2006-961535

  • 41

    SelloumLBouricheHTigrineCBoudoukhaC. Anti-inflammatory effect of rutin on rat paw oedema, and on neutrophils chemotaxis and degranulation. Exp Toxicologic Pathol (2003) 54:313–8. doi: 10.1078/0940-2993-00260

  • 42

    LeeSJungSHLeeYSYamadaMKimB-KOhuchiKet al. Antiinflammatory activity of hyperin fromAcanthopanax chiisanensis roots. Arch pharmacal Res (2004) 27:628–32. doi: 10.1007/BF02980162

  • 43

    PanC-HKimESJungSHNhoCWLeeJK. Tectorigenin inhibits IFN-γ/LPS-induced inflammatory responses in murine macrophage RAW 264.7 cells. Arch pharmacal Res (2008) 31:1447–56. doi: 10.1007/s12272-001-2129-7

  • 44

    SahaSSadhukhanPSilPC. Mangiferin: A xanthonoid with multipotent anti-inflammatory potential. Biofactors (2016) 42:459–74. doi: 10.1002/biof.1292

  • 45

    HartPBrandCCarsonCRileyTPragerRFinlay-JonesJ. Terpinen-4-ol, the main component of the essential oil of melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. Inflammation Res (2000) 49:619–26. doi: 10.1007/s000110050639

  • 46

    CosynsJ-P. Aristolochic acid and ‘Chinese herbs nephropathy’. Drug Saf (2003) 26:3348. doi: 10.2165/00002018-200326010-00004

  • 47

    FanhchaksaiKKodchakornKPothacharoenPKongtawelertP. Effect of sesamin against cytokine production from influenza type a H1N1-induced peripheral blood mononuclear cells: Computational and experimental studies. In Vitro Cell Dev Biology-Animal (2016) 52:107–19. doi: 10.1007/s11626-015-9950-7

  • 48

    XuJ-JLiuZTangWWangG-CChungHYLiuQ-Yet al. Tangeretin from citrus reticulate inhibits respiratory syncytial virus replication and associated inflammation in vivo. J Agric Food Chem (2015) 63:9520–7. doi: 10.1021/acs.jafc.5b03482

  • 49

    HaggagYAEl-AshmawyNEOkashaKM. Is hesperidin essential for prophylaxis and treatment of COVID-19 infection? Med Hypotheses (2020) 144:109957–8. doi: 10.1016/j.mehy.2020.109957

  • 50

    TutunchiHNaeiniFOstadrahimiAHosseinzadeh-AttarMJ. Naringenin, a flavanone with antiviral and anti-inflammatory effects: A promising treatment strategy against COVID-19. Phytotherapy Res (2020) 34:3137–47. doi: 10.1002/ptr.6781

  • 51

    ChiangLCNgLTChengPWChiangWLinCC. Antiviral activities of extracts and selected pure constituents of ocimum basilicum. Clin Exp Pharmacol Physiol (2005) 32:811–6. doi: 10.1111/j.1440-1681.2005.04270.x

  • 52

    BhattacharjeeBChatterjeeJ. Identification of proapoptopic, anti-inflammatory, anti-proliferative, anti-invasive and anti-angiogenic targets of essential oils in cardamom by dual reverse virtual screening and binding pose analysis. Asian Pacific J Cancer Prev (2013) 14:3735–42. doi: 10.7314/APJCP.2013.14.6.3735

  • 53

    Carballo-VillalobosAGonzález-TrujanoMLópez-MuñozF. Evidence of mechanism of action of anti-inflammatory/antinociceptive activities of acacetin. Eur J Pain (2014) 18:396405. doi: 10.1002/j.1532-2149.2013.00378.x

  • 54

    RogerioAKanashiroAFontanariCDa SilvaELucisano-ValimYSoaresEet al. Anti-inflammatory activity of quercetin and isoquercitrin in experimental murine allergic asthma. Inflammation Res (2007) 56:402–8. doi: 10.1007/s00011-007-7005-6

  • 55

    SchwarzSSauterDWangKZhangRSunBKariotiAet al. Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus. Planta Med (2014) 80:177–82. doi: 10.1055/s-0033-1360277

  • 56

    Murbach Teles AndradeBFContiBJSantiagoKBFernandesASforcinJM. C ymbopogon martinii essential oil and geraniol at noncytotoxic concentrations exerted immunomodulatory/anti-inflammatory effects in human monocytes. J Pharm Pharmacol (2014) 66:1491–6. doi: 10.1111/jphp.12278

  • 57

    LeeJK. Anti-inflammatory effects of eriodictyol in lipopolysaccharidestimulated raw 264.7 murine macrophages. Arch Pharmacal Res (2011) 34:671–9. doi: 10.1007/s12272-011-0418-3

  • 58

    FreireRSMoraisSMCatunda-JuniorFEAPinheiroDC. Synthesis and antioxidant, anti-inflammatory and gastroprotector activities of anethole and related compounds. Bioorganic medicinal Chem (2005) 13:4353–8. doi: 10.1016/j.bmc.2005.03.058

  • 59

    AgrawalPKAgrawalCBlundenG. Quercetin: antiviral significance and possible COVID-19 integrative considerations. Natural Product Commun (2020) 15:110. doi: 10.1177/1934578X20976293

  • 60

    SinKSKimHPLeeWCPachalyP. Pharmacological activities of the constituents of atractylodes rhizomes. Arch Pharmacal Res (1989) 12:236–8. doi: 10.1007/BF02911051

  • 61

    HuangHChengZShiHXinWWangTTYuL. Isolation and characterization of two flavonoids, engeletin and astilbin, from the leaves of engelhardia roxburghiana and their potential anti-inflammatory properties. J Agric Food Chem (2011) 59:4562–9. doi: 10.1021/jf2002969

  • 62

    LeeCWParkNHKimJWUmBHShpatovAShultsEet al. Study of skin anti-ageing and anti-inflammatory effects of dihydroquercetin, natural triterpenoinds, and their synthetic derivatives. Russian J Bioorganic Chem (2012) 38:328–34. doi: 10.1134/S1068162012030028

  • 63

    HwaJSJinYCLeeYSKoYSKimYMShiLYet al. 2-methoxycinnamaldehyde from cinnamomum cassia reduces rat myocardial ischemia and reperfusion injury in vivo due to HO-1 induction. J ethnopharmacol (2012) 139:605–15. doi: 10.1016/j.jep.2011.12.001

  • 64

    KimD-HYooT-HLeeSHKangHYNamBYKwakSJet al. Gamma linolenic acid exerts anti-inflammatory and anti-fibrotic effects in diabetic nephropathy. Yonsei Med J (2012) 53:1165–75. doi: 10.3349/ymj.2012.53.6.1165

  • 65

    PanP-HLinS-YOuY-CChenW-YChuangY-HYenY-Jet al. Stearic acid attenuates cholestasis-induced liver injury. Biochem Biophys Res Commun (2010) 391:1537–42. doi: 10.1016/j.bbrc.2009.12.119

  • 66

    XiaSNiYZhouQXiangHSuiHShangD. Emodin attenuates severe acute pancreatitis via antioxidant and anti-inflammatory activity. Inflammation (2019) 42:2129–38. doi: 10.1007/s10753-019-01077-z

  • 67

    ShangXHeXLiuHWenBTanTXuCet al. Stachyose prevents intestinal mucosal injury in the immunosuppressed mice. Starch-Stärke (2020) 72:19000731900074. doi: 10.1002/star.201900073

  • 68

    ZhouY-ZLiXGongW-XTianJ-SGaoX-XGaoLet al. Protective effect of isoliquiritin against corticosterone-induced neurotoxicity in PC12 cells. Food Funct (2017) 8:1235–44. doi: 10.1039/C6FO01503D

  • 69

    AbdizadehRHadizadehFAbdizadehT. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2. Mol Diversity (2021) 16:1053–76. doi: 10.1007/s11030-021-10230-6

  • 70

    RichardSA. Exploring the pivotal immunomodulatory and anti-inflammatory potentials of glycyrrhizic and glycyrrhetinic acids. Mediators Inflammation (2021) 2021:115. doi: 10.1155/2021/6699560

  • 71

    LeeJYParkW. Anti-inflammatory effect of wogonin on RAW 264.7 mouse macrophages induced with polyinosinic-polycytidylic acid. Molecules (2015) 20:6888–900. doi: 10.3390/molecules20046888

  • 72

    RoyAParkH-JAbdulQAJungHAChoiJS. Pulegone exhibits anti-inflammatory activities through the regulation of NF-κB and nrf-2 signaling pathways in LPS-stimulated RAW 264.7 cells. Natural Product Sci (2018) 24:2835. doi: 10.20307/nps.2018.24.1.28

  • 73

    HuiYWangXYuZFanXCuiBZhaoTet al. Scoparone as a therapeutic drug in liver diseases: Pharmacology, pharmacokinetics and molecular mechanisms of action. Pharmacol Res (2020) 160:105170–2. doi: 10.1016/j.phrs.2020.105170

  • 74

    LengLLiMLiWMouDLiuGMaJet al. Sera proteomic features of active and recovered COVID-19 patients: potential diagnostic and prognostic biomarkers. Signal transduction targeted Ther (2021) 6:13. doi: 10.1038/s41392-021-00612-5

  • 75

    TaheryNKhodadostMSherafatSJTaviraniMRAhmadiNMontazerFet al. C-reactive protein as a possible marker for severity and mortality of COVID-19 infection. Gastroenterol Hepatol From Bed to Bench (2021) 14:S118–22.

  • 76

    VavougiosGDBrezaMMavridisTKrogfeltKA. FYN, SARS-CoV-2, and IFITM3 in the neurobiology of alzheimer's disease. Brain Disord (2021) 3:100022–3. doi: 10.1016/j.dscb.2021.100022

  • 77

    ChenLZhengS. Understand variability of COVID-19 through population and tissue variations in expression of SARS-CoV-2 host genes. Inf Med unlocked (2020) 21:100443–3. doi: 10.1016/j.imu.2020.100443

  • 78

    HarfordJBKimSSPirolloKFChangEH. TP53 gene therapy as a potential treatment for patients with COVID-19. Viruses (2022) 14:739–40. doi: 10.3390/v14040739

  • 79

    SavastanoAIbáñez De OpakuaARankovicMZweckstetterM. Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates. Nat Commun (2020) 11:110. doi: 10.1038/s41467-020-19843-1

  • 80

    XiaQDXunYLuJLLuYCYangYYZhouPet al. Network pharmacology and molecular docking analyses on lianhua qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19. Cell proliferation (2020) 53:12949–9. doi: 10.1111/cpr.12949

  • 81

    ShahTShahZXiaK-YBalochZ. Therapeutic mechanisms and impact of traditional Chinese medicine on COVID-19 and other influenza diseases. Pharmacol Research-Modern Chin Med (2021) 2:100029–9. doi: 10.1016/j.prmcm.2021.100029

  • 82

    ZhangXGaoRZhouZTangXLinJWangLet al. A network pharmacology based approach for predicting active ingredients and potential mechanism of lianhuaqingwen capsule in treating COVID-19. Int J Med Sci (2021) 18:1866–7. doi: 10.7150/ijms.53685

  • 83

    TaoQDuJLiXZengJTanBXuJet al. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of huashi baidu formula in the treatment of COVID-19. Drug Dev Ind Pharm (2020) 46:1345–53. doi: 10.1080/03639045.2020.1788070

  • 84

    Kuri-CervantesLPampenaMBMengWRosenfeldAMIttnerCAWeismanARet al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol (2020) 5:eabd7114. doi: 10.1126/sciimmunol.abd7114

  • 85

    LuoWLiY-XJiangL-JChenQWangTYeD-W. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol Sci (2020) 41:531–43. doi: 10.1016/j.tips.2020.06.007

  • 86

    BouhaddouMMemonDMeyerBWhiteKMRezeljVVMarreroMCet al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell (2020) 182:685712.e619. doi: 10.1016/j.cell.2020.06.034

  • 87

    KiewL-VChangC-YHuangS-YWangP-WHehC-HLiuC-Tet al. Development of flexible electrochemical impedance spectroscopy-based biosensing platform for rapid screening of SARS-CoV-2 inhibitors. Biosensors Bioelectronics (2021) 183:113213–3. doi: 10.1016/j.bios.2021.113213

  • 88

    Abu-FarhaMThanarajTAQaddoumiMGHashemAAbubakerJAl-MullaF. The role of lipid metabolism in COVID-19 virus infection and as a drug target. Int J Mol Sci (2020) 21:3544–5. doi: 10.3390/ijms21103544

  • 89

    BarhDAljabaliAATambuwalaMMTiwariSSerrano-ArocaÁ.AlzahraniKJet al. Predicting COVID-19–comorbidity pathway crosstalk-based targets and drugs: towards personalized COVID-19 management. Biomedicines (2021) 9:556–8. doi: 10.3390/biomedicines9050556

  • 90

    ChuHZhouJWongBH-YLiCChanJF-WChengZ-Set al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J Infect Dis (2016) 213:904–14. doi: 10.1093/infdis/jiv380

Summary

Keywords

COVID-19, herb, target, active component, anti-inflammatory, anti-SARS-CoV-2

Citation

Wang Z, Zhan J and Gao H (2022) Computer-aided drug design combined network pharmacology to explore anti-SARS-CoV-2 or anti-inflammatory targets and mechanisms of Qingfei Paidu Decoction for COVID-19. Front. Immunol. 13:1015271. doi: 10.3389/fimmu.2022.1015271

Received

09 August 2022

Accepted

05 December 2022

Published

23 December 2022

Volume

13 - 2022

Edited by

Alfonso J. Rodriguez-Morales, Fundacion Universitaria Autónoma de las Américas, Colombia

Reviewed by

Zhonglei Wang, Qufu Normal University, China; Trina Ekawati Tallei, Sam Ratulangi University, Indonesia

Updates

Copyright

*Correspondence: Hongwei Gao,

This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics